Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32374
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNguyen, James-
dc.contributor.authorWellard, Cameron-
dc.contributor.authorChung, Eliza-
dc.contributor.authorCheah, Chan Y-
dc.contributor.authorDickinson, Michael-
dc.contributor.authorDoo, Nicole Wong-
dc.contributor.authorKeane, Colm-
dc.contributor.authorTalaulikar, Dipti-
dc.contributor.authorBerkahn, Leanne-
dc.contributor.authorMorgan, Susan-
dc.contributor.authorHamad, Nada-
dc.contributor.authorCochrane, Tara-
dc.contributor.authorJohnston, Anna M-
dc.contributor.authorForsyth, Cecily-
dc.contributor.authorOpat, Stephen-
dc.contributor.authorBarraclough, Allison-
dc.contributor.authorMutsando, Howard-
dc.contributor.authorRatnasingam, Sumita-
dc.contributor.authorGiri, Pratyush-
dc.contributor.authorWood, Erica M-
dc.contributor.authorMcQuilten, Zoe K-
dc.contributor.authorHawkes, Eliza A-
dc.date2022-
dc.date.accessioned2023-03-22T02:18:59Z-
dc.date.available2023-03-22T02:18:59Z-
dc.date.issued2023-04-
dc.identifier.citationEuropean journal of haematology 2023; 110(4)en_US
dc.identifier.issn1600-0609-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32374-
dc.description.abstractComprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real-world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first-line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced-stage disease, and 48% of patients with the early-stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥60 years of age with advanced-stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early-stage disease, and 88% in advanced-stage disease. Early progression-free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.en_US
dc.language.isoeng-
dc.subjectclassical Hodgkin lymphomaen_US
dc.subjectclinical characteristicsen_US
dc.subjectdemographicen_US
dc.subjecttreatment regimenen_US
dc.titleClinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean journal of haematologyen_US
dc.identifier.affiliationEastern Health, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationMonash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationMonash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSir Charles Gairdner Hospital and Medical School, University of Western Australia, Western Australia, Australia.en_US
dc.identifier.affiliationPeter MacCallum Cancer Centre; Royal Melbourne Hospital, and the Sir Peter MacCallum Department of Oncology at the University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationConcord Repatriation General Hospital; Concord Clinical School, University of Sydney, Concord, New South Wales, Australia.en_US
dc.identifier.affiliationPrincess Alexandra Hospital, Queensland, Australia.en_US
dc.identifier.affiliationCanberra Health Services, The Australian National University, Australian Capital Territory, Australia.en_US
dc.identifier.affiliationAuckland City Hospital, Auckland, New Zealand.en_US
dc.identifier.affiliationAlfred Health, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSt Vincent's Hospital Sydney, Sydney, New South Wales, Australia.en_US
dc.identifier.affiliationGold Coast University Hospital, Griffith University, Southport, Queensland, Australia.en_US
dc.identifier.affiliationRoyal Hobart Hospital, Tasmania, Australia.en_US
dc.identifier.affiliationGosford Hospital, New South Wales, Australia.en_US
dc.identifier.affiliationMonash Health, Victoria, Australia.en_US
dc.identifier.affiliationFiona Stanley Hospital, Western Australia, Australia.en_US
dc.identifier.affiliationToowoomba Hospital, Queensland, Australia.en_US
dc.identifier.affiliationUniversity Hospital Geelong, Victoria, Australia.en_US
dc.identifier.affiliationRoyal Adelaide Hospital, South Australia, Australia.en_US
dc.identifier.affiliationMonash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationMonash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationMonash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.doi10.1111/ejh.13915en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3206-2188en_US
dc.identifier.orcid0000-0001-7988-1565en_US
dc.identifier.orcid0000-0002-1492-5966en_US
dc.identifier.orcid0000-0003-3725-3397en_US
dc.identifier.orcid0000-0002-2668-1399en_US
dc.identifier.orcid0000-0001-5959-5203en_US
dc.identifier.orcid0000-0003-1615-0540en_US
dc.identifier.orcid0000-0001-7527-2340en_US
dc.identifier.orcid0000-0001-9698-7185en_US
dc.identifier.orcid0000-0002-0376-2559en_US
dc.identifier.pubmedid36539351-
dc.description.volume110-
dc.description.issue4-
dc.description.startpage386-
dc.description.endpage395-
dc.subject.meshtermssecondaryBleomycin/therapeutic use-
dc.subject.meshtermssecondaryDoxorubicin/therapeutic use-
dc.subject.meshtermssecondaryVinblastine/therapeutic use-
dc.subject.meshtermssecondaryDacarbazine/therapeutic use-
dc.subject.meshtermssecondaryAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
local.name.researcherBarraclough, Allison
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

82
checked on Jun 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.